[] Genzyme Corporate    [] Genzyme Websites   

Safety Profile

95.8% of SYNVISC® patients were free of treatment-related adverse reactions or effects, according to one of the largest viscosupplementation studies conducted to evaluate SYNVISC's safety profile in standard clinical practice.1 When adverse effects occurred, they were easily managed and did not interfere with the benefits of SYNVISC therapy.1,2,3

SYNVISC demonstrates a low incidence of treatment-related adverse events

95% Free

Prospective, observational study of 4,253 patients with OA knee pain to evaluate the short-term tolerability and effectiveness of SYNVISC in standard clinical practice.1

More findings, more answers

Viscosupplementation safety has been well documented, but your patients may still have questions about local adverse reactions and effects. These clinical trial results should help you address any concerns:

  • Knee pain/swelling occurred in 2.2% of first course treatment injections (7.2% of patients)
  • 97.6% of 12,699 injections SYNVISC administered by 840 orthopaedic surgeons were free of local adverse events (AEs)1
  • Local adverse events with SYNVISC are generally mild to moderate, easily managed and do not preclude clinical benefit.1,2,3

View the Complete Prescribing Information for SYNVISC (PDF) for full details.


1. Kemper F, Gebhardt U, Meng T, Murray C. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin. 2005;21(8):1261-1269

View Research Bibliography

1. Kemper F, Gebhardt U, Meng T, Murray C. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin. 2005;21(8):1261-1269

View Research Bibliography

1. Kemper F, Gebhardt U, Meng T, Murray C. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin. 2005;21(8):1261-1269

View Research Bibliography

1. Kemper F, Gebhardt U, Meng T, Murray C. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin. 2005;21(8):1261-1269

View Research Bibliography

1. Kemper F, Gebhardt U, Meng T, Murray C. Tolerability and short-term effectiveness of hylan G-F 20 in 4253 patients with osteoarthritis of the knee in clinical practice. Curr Med Res Opin. 2005;21(8):1261-1269

View Research Bibliography

2. Waddell DD. The tolerability of viscosupplementation: low incidence and clinical management of local adverse events. Curr Med Res Opin.2003;19:575-580.

View Research Bibliography

2. Waddell DD. The tolerability of viscosupplementation: low incidence and clinical management of local adverse events. Curr Med Res Opin.2003;19:575-580.

View Research Bibliography

3. Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, De Médicis R. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol. 1996;23:1579-1585.

View Research Bibliography

3. Lussier A, Cividino AA, McFarlane CA, Olszynski WP, Potashner WJ, De Médicis R. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol. 1996;23:1579-1585.

View Research Bibliography